Inkef

Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Provable Markets is a financial services company that offers market participants a secure, unified, and pragmatic access point for cash and synthetic equity finance trading. The company has developed an SEC registered Alternative Trading System (ATS) named Aurora. Provable Markets aims to create a paradigm shift in how financial markets operate, with a focus on transparency and solving some of the biggest challenges in the financial industry. The company has a community of passionate people working towards these goals.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Silverflow is a payment processing technology company based in Amsterdam, Netherlands, founded in 2019. The company offers a cloud-based payments platform that enables payment service providers (PSPs) to gain direct access to card networks. This innovative platform allows PSPs to enhance their services by instantly adding new functionalities and obtaining real-time insights into transaction fees. Additionally, Silverflow provides smart data directly from the networks, which helps payment providers serve their merchants more effectively. By streamlining data flow and utilizing basic application programming interfaces, Silverflow aims to improve agility, transparency, and security in global payment operations, benefiting not only PSPs but also merchants and acquirers.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Anavo Therapeutics is pioneering the systematic drugging of phosphatases, a target area that has long been deemed undruggable. The company focuses on developing first-in-class therapeutic programs, particularly in oncology, leveraging its expertise in phosphatase-driven disease biology and drug discovery. Anavo aims to create a diverse pipeline of therapeutics across various indications by fostering strategic partnerships and collaborations. Through this innovative approach, Anavo seeks to unlock the potential of phosphatase-targeted allosteric modulators, advancing the field of targeted therapies in medicine.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

Quantum Motion Technologies is focused on developing universal quantum computers utilizing silicon-based, CMOS-compatible processes. The company aims to address key challenges in quantum computing, such as fault tolerance and qubit redundancy, by creating scalable architectural technologies. By leveraging complementary metal-oxide semiconductor processing, Quantum Motion strives to achieve greater qubit density, enabling the construction of large-scale quantum systems. This approach not only enhances the performance of quantum computers but also assists clients in the quantum technology sector in overcoming significant errors and critical challenges in quantum information processing.

Happeo is a digital workplace platform that offers an advanced intranet solution for teams to manage knowledge and internal communications effectively. The platform features a template-based page builder, integrations, and a universal search functionality that simplifies access to various company tools. Happeo's user-friendly design makes it suitable for organizations of all sizes, with notable clients like Doctolib, GANT, and Marqeta utilizing its services to enhance team alignment and productivity. The platform supports internal communicators by managing calendars, files, conferencing, and projects, while also integrating with CRM and HR systems. Happeo aims to foster engagement and create a positive employee experience, achieving adoption rates that are three times higher than the industry average.

Baserow is a no-code, open-source database platform founded in 2021 by Bram Wiepjes and Olivier Maes. It allows non-technical teams to capture and organize data effectively, facilitating intelligent business insights and process automation. The platform enables users to manage essential business operations without the limitations often associated with traditional SaaS tools, such as data governance, scalability, and security concerns. Baserow provides a range of tools for creating flexible checklists, organizing collections, and managing customer contacts, along with various templates for diverse applications, from home improvement to inventory management. This empowers users to build custom applications without requiring prior coding experience.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

ChannelEngine is a cloud-based multichannel platform that facilitates seamless integration between sellers' systems and international marketplaces. By connecting webshops with various e-commerce platforms, ChannelEngine enables brands, distributors, and retailers to automate their sales processes, including order and returns management. The platform is designed to optimize sales performance while minimizing operational time, thereby enhancing profitability and market reach. With an advanced management suite and a rich partner ecosystem, ChannelEngine empowers businesses to fully leverage their international sales potential.

Scenic Biotech, established in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies to combat cancer and rare genetic diseases. The company's core focus is to identify and harness disease-suppressing genes, which can act as an "off-switch" for genetic disorders, thereby creating novel drug targets and therapies. By leveraging genomics, Scenic Biotech aims to revolutionize the treatment of severe diseases by tackling them at their genetic source.

TargED Biopharmaceuticals is a biotechnology company focused on developing innovative biological drugs aimed at enhancing the treatment of thrombosis. The company utilizes small antibodies, known as VhH, to deliver enzymes directly to the sites of thrombus, facilitating targeted thrombolysis. This approach allows for effective treatment regardless of the blood clot's composition, thereby enabling healthcare professionals to accelerate patient care and improve outcomes for those affected by thrombosis.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

AmbAgon Therapeutics is a biotechnology company focused on developing small-molecule therapeutics for cancer treatment. The company specializes in research aimed at stabilizing the interactions of oncogenic proteins, thereby enhancing the activity of tumor-suppressing proteins. By targeting these proteins, AmbAgon Therapeutics seeks to address significant unmet clinical needs in oncology that conventional treatment methods have struggled to meet. Founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin, the company aims to provide innovative solutions in cancer care through its unique approach to drug development.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Silverflow is a payment processing technology company based in Amsterdam, Netherlands, founded in 2019. The company offers a cloud-based payments platform that enables payment service providers (PSPs) to gain direct access to card networks. This innovative platform allows PSPs to enhance their services by instantly adding new functionalities and obtaining real-time insights into transaction fees. Additionally, Silverflow provides smart data directly from the networks, which helps payment providers serve their merchants more effectively. By streamlining data flow and utilizing basic application programming interfaces, Silverflow aims to improve agility, transparency, and security in global payment operations, benefiting not only PSPs but also merchants and acquirers.

Shapeways Holdings Inc. is a 3D printing marketplace and community that enables individuals to create, buy, and sell custom products. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company offers a wide range of products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Shapeways operates on a model of on-demand printing, allowing for the customization and personalization of each order. By providing access to advanced 3D printing technology, the platform empowers users to turn their ideas into physical products, fostering creativity and entrepreneurship. Shapeways aims to democratize the manufacturing process by fully digitizing it, making industrial-grade additive manufacturing accessible to a broader audience.

Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.

Cardior Pharmaceuticals GmbH is a biotechnology company based in Hanover, Germany, established in 2016. The company specializes in the development of non-coding RNA-based therapeutics aimed at treating and preventing heart disease, a leading cause of mortality in the western world. Its primary focus is on CDR-132X, an oligonucleotide-based inhibitor that targets a molecular master switch (microRNA) responsible for pathological changes in the heart resulting from stress or injury. By advancing innovative therapies, Cardior Pharmaceuticals aims to address significant health challenges associated with cardiovascular conditions.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Urban Sports Club is a Berlin-based company founded in 2012 by Moritz Kreppel and Benjamin Roth, focused on promoting healthy and active lifestyles through a flexible sports membership model. It offers access to over 50 different sports activities, including gym workouts, swimming, yoga, and team sports, available at more than 10,000 partner venues across Germany, France, Italy, Spain, Portugal, and Belgium. The company targets both individuals and corporate clients, allowing members to enjoy a diverse range of wellness and fitness options. Following its initial bootstrapping phase, Urban Sports Club expanded through strategic acquisitions of several German competitors, including Somuchmore, FITrate, INTERFIT, and OneFit, enhancing its service offerings and market presence. The company's innovative approach aims to reinvent the leisure and corporate sports market by providing a comprehensive and convenient sports experience for its members.

Sentinels is an AI-powered startup specializing in transaction monitoring solutions for the financial industry. The company offers a cloud-based platform that enhances compliance efforts for fintech companies by providing data-driven insights to combat money laundering and other illegal activities. By optimizing anti-money laundering processes, Sentinels enables compliance experts to gain real-time, actionable information, thereby improving the effectiveness of their monitoring efforts.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Anavo Therapeutics is pioneering the systematic drugging of phosphatases, a target area that has long been deemed undruggable. The company focuses on developing first-in-class therapeutic programs, particularly in oncology, leveraging its expertise in phosphatase-driven disease biology and drug discovery. Anavo aims to create a diverse pipeline of therapeutics across various indications by fostering strategic partnerships and collaborations. Through this innovative approach, Anavo seeks to unlock the potential of phosphatase-targeted allosteric modulators, advancing the field of targeted therapies in medicine.

Lengoo specializes in unlocking the potential of language data for enterprises through its advanced technology platform, HALOS. This platform enables organizations to build and operate custom language models at scale while maintaining high standards of IT security and intellectual property protection. For over five years, Lengoo has assisted global industry leaders and emerging companies in securely adopting artificial intelligence solutions. The company offers language intelligence applications, such as Flow, and a robust API that empower office workers with reliable virtual AI partners, enhancing organizational efficiency and supporting sustained growth.

ChannelEngine is a cloud-based multichannel platform that facilitates seamless integration between sellers' systems and international marketplaces. By connecting webshops with various e-commerce platforms, ChannelEngine enables brands, distributors, and retailers to automate their sales processes, including order and returns management. The platform is designed to optimize sales performance while minimizing operational time, thereby enhancing profitability and market reach. With an advanced management suite and a rich partner ecosystem, ChannelEngine empowers businesses to fully leverage their international sales potential.

EclecticIQ is a company specializing in threat intelligence and cybersecurity solutions. It develops advanced technology for threat hunting and response, aimed at enhancing organizations' defenses against cyber adversaries. The company's platform integrates and interprets intelligence data sourced from open sources, commercial suppliers, and industry partnerships. This enables enterprises to bolster their detection, prevention, and response capabilities by embedding actionable intelligence into their cybersecurity infrastructures. Through its offerings, EclecticIQ strives to empower organizations to effectively combat evolving cyber threats.

Silverflow is a payment processing technology company based in Amsterdam, Netherlands, founded in 2019. The company offers a cloud-based payments platform that enables payment service providers (PSPs) to gain direct access to card networks. This innovative platform allows PSPs to enhance their services by instantly adding new functionalities and obtaining real-time insights into transaction fees. Additionally, Silverflow provides smart data directly from the networks, which helps payment providers serve their merchants more effectively. By streamlining data flow and utilizing basic application programming interfaces, Silverflow aims to improve agility, transparency, and security in global payment operations, benefiting not only PSPs but also merchants and acquirers.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Happeo is a digital workplace platform that offers an advanced intranet solution for teams to manage knowledge and internal communications effectively. The platform features a template-based page builder, integrations, and a universal search functionality that simplifies access to various company tools. Happeo's user-friendly design makes it suitable for organizations of all sizes, with notable clients like Doctolib, GANT, and Marqeta utilizing its services to enhance team alignment and productivity. The platform supports internal communicators by managing calendars, files, conferencing, and projects, while also integrating with CRM and HR systems. Happeo aims to foster engagement and create a positive employee experience, achieving adoption rates that are three times higher than the industry average.

Quantum Motion Technologies is focused on developing universal quantum computers utilizing silicon-based, CMOS-compatible processes. The company aims to address key challenges in quantum computing, such as fault tolerance and qubit redundancy, by creating scalable architectural technologies. By leveraging complementary metal-oxide semiconductor processing, Quantum Motion strives to achieve greater qubit density, enabling the construction of large-scale quantum systems. This approach not only enhances the performance of quantum computers but also assists clients in the quantum technology sector in overcoming significant errors and critical challenges in quantum information processing.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Based in Cambridge, Massachusetts, the company utilizes proprietary platforms and biomarkers to create precision medicines targeting genetically validated disease-causing alterations. Its pipeline includes various treatments aimed at specific subtypes of ALS, such as therapies designed to restore dysfunctional cellular waste clearance, manage overactive neurons to prevent cell death, and eliminate toxic proteins. QurAlis aims to advance its antisense oligonucleotides and small molecule programs to address the most prevalent forms of ALS, ultimately working to halt disease progression and improve patient outcomes. The company was incorporated in 2016 and operates as a subsidiary of Q-State Biosciences, Inc.

Remote is a global HR solutions provider that facilitates international hiring and payroll management for distributed teams. They offer a platform designed to help companies recruit top talent worldwide, ensuring compliance with local laws while streamlining project allocation and payments. This enables businesses to expand their workforce globally, enhancing productivity and employment opportunities.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Draupnir Bio is focused on developing innovative cholesterol-lowering medications aimed at preventing blood clots in the heart with greater efficacy than existing treatments. The company utilizes a platform that explores the glycome to create novel therapeutics, employing advanced techniques in array technology, protein chemistry, and carbohydrate chemistry. This platform enables the synthesis, screening, and selection of potent heparan sulfate glycomimetic drug candidates, targeting cardiovascular, inflammatory, and infectious diseases. Additionally, Draupnir Bio's technology includes the development of protein degraders that can target extracellular disease proteins, potentially addressing a wide range of unmet therapeutic needs across various medical conditions. This approach promises more convenient and accessible treatment options compared to traditional injectable therapies.

Cashforce BV, established in 2013, is a Belgian-based company with global offices, specializing in smart cash flow management and forecasting. Its platform integrates with various ERPs and banking systems, enabling users to predict cash inflows and outflows, identify potential shortages or surpluses, and simulate multiple cash flow scenarios. Cashforce serves diverse sectors, including wholesale, transportation, and manufacturing, and has a strategic alliance with Treasury Intelligence Solutions GmbH.

EclecticIQ is a company specializing in threat intelligence and cybersecurity solutions. It develops advanced technology for threat hunting and response, aimed at enhancing organizations' defenses against cyber adversaries. The company's platform integrates and interprets intelligence data sourced from open sources, commercial suppliers, and industry partnerships. This enables enterprises to bolster their detection, prevention, and response capabilities by embedding actionable intelligence into their cybersecurity infrastructures. Through its offerings, EclecticIQ strives to empower organizations to effectively combat evolving cyber threats.

Urban Sports Club is a Berlin-based company founded in 2012 by Moritz Kreppel and Benjamin Roth, focused on promoting healthy and active lifestyles through a flexible sports membership model. It offers access to over 50 different sports activities, including gym workouts, swimming, yoga, and team sports, available at more than 10,000 partner venues across Germany, France, Italy, Spain, Portugal, and Belgium. The company targets both individuals and corporate clients, allowing members to enjoy a diverse range of wellness and fitness options. Following its initial bootstrapping phase, Urban Sports Club expanded through strategic acquisitions of several German competitors, including Somuchmore, FITrate, INTERFIT, and OneFit, enhancing its service offerings and market presence. The company's innovative approach aims to reinvent the leisure and corporate sports market by providing a comprehensive and convenient sports experience for its members.

Comet Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. It specializes in developing novel small-molecule treatments targeting various diseases, particularly orphan neurological disorders. The company's core innovation is its CoEnzyme metabolism platform, which aims to restore dysregulated CoEnzyme A metabolism. This therapeutic approach enables healthcare providers to address significant unmet medical needs in the treatment of these complex conditions.

Withlocals is an online marketplace established in 2013 that specializes in personalized travel experiences. The platform offers over 1,200 customizable and private tours led by approximately 900 verified local hosts across various international cities, primarily in Europe and Asia. Withlocals aims to connect people and cultures through travel, allowing travelers to engage with destinations in an authentic manner, guided by locals who provide insights and experiences off the beaten path. The marketplace facilitates direct connections between hosts and tourists, making personalized travel accessible and affordable for a broad audience. Users can choose activities based on their interests, including food, music, and sports, ensuring a tailored experience that reflects their passions.

Calypso Biotech SA is an immunotherapy biotechnology company based in Plan-les-Ouates, Switzerland, founded in 2013 as a spin-off from Merck Serono. The company specializes in discovering and developing monoclonal antibodies aimed at treating immune pathologies, particularly for conditions with significant unmet medical needs, including severe gastrointestinal diseases. Calypso Biotech operates as a semi-virtual organization, leveraging a highly experienced management team with expertise in drug development. The company focuses on creating substantial value for investors through a portfolio of unique proprietary antibody candidates designed to control homeostasis and improve treatment outcomes for patients.

Aidence is a company that develops intelligent software aimed at improving the management of lung cancer. With a team of over 80 professionals, including data scientists, software engineers, and medical experts, Aidence has created its first clinical application, Veye Lung Nodules. This AI-driven solution assists in the management of pulmonary nodules identified in CT scans and is currently in use in routine clinical settings and lung cancer screening programs throughout Europe. The platform transforms complex data into practical information, enabling healthcare providers to enhance patient outcomes through quicker diagnoses, reduced misdiagnosis risks, and improved detection of early-stage lung cancer.

GeoPhy is a developer of an artificial intelligence-driven property analytics platform that leverages both traditional and alternative data sources to deliver instant and accurate valuations for commercial real estate. By utilizing machine learning, GeoPhy helps real estate professionals identify market opportunities and manage risks effectively. The platform provides valuable insights into commercial property values and the factors influencing them, allowing users to assess opportunities based on specific market criteria. Through its innovative approach, GeoPhy aims to enhance transparency and efficiency in the commercial real estate sector.

Polarsteps is a travel technology company that specializes in trip planning, tracking, and sharing. Its core product is a mobile application that automatically records users' travel routes, key locations, and photos, plotting them on a world map that can be shared with friends and family. This service allows users to effortlessly create and preserve travel memories.

GitLab Inc. is a software development company that provides a comprehensive DevSecOps platform designed to enhance the software development lifecycle. Founded in 2011 and headquartered in San Francisco, California, GitLab offers its services through a single application, which includes tools for version control, continuous integration and deployment, code reviews, issue tracking, and collaboration. This unified platform allows organizations to efficiently plan, build, secure, and deploy software while ensuring visibility and control throughout the process. GitLab serves a diverse clientele, ranging from startups to large enterprises, with an estimated 30 million registered users globally. The company operates on an all-remote model, employing over 1,350 team members across more than 65 countries. GitLab is built on open-source principles and benefits from a vibrant community of developers, continuously driving innovations in the DevOps space.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Rainier Therapeutics is a biotechnology company focused on developing targeted therapies for bladder cancer. The company specializes in Vofatamab, a human monoclonal antibody designed to inhibit the activity of FGFR3 (fibroblast growth factor receptor 3), which is crucial in the treatment of both early-stage and metastatic bladder cancer. Founded in 2010 and based in San Leandro, California, Rainier Therapeutics was previously known as BioClin Therapeutics before rebranding in November 2018. Through its innovative approach, Rainier Therapeutics aims to enhance treatment options for patients suffering from this challenging disease.

OneFit is a fitness aggregator that offers users access to a wide variety of gyms and studios through a single monthly membership. This all-in-one sports membership allows individuals to explore different fitness options, including various workout classes and training environments, without the need for multiple subscriptions. By streamlining the fitness experience, OneFit caters to a diverse clientele seeking flexibility and convenience in their workout routines.

Shapeways Holdings Inc. is a 3D printing marketplace and community that enables individuals to create, buy, and sell custom products. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company offers a wide range of products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Shapeways operates on a model of on-demand printing, allowing for the customization and personalization of each order. By providing access to advanced 3D printing technology, the platform empowers users to turn their ideas into physical products, fostering creativity and entrepreneurship. Shapeways aims to democratize the manufacturing process by fully digitizing it, making industrial-grade additive manufacturing accessible to a broader audience.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Health Value Creation is developing two surgical devices, a diagnostic tool and a trocar closure device. The first device helps prevent anastomotic leakages after bowel surgery by predicting the quality of the anastomosis during surgery, thereby reducing post-operative complications and lowering healthcare costs. The second device is a trocar closure device for faster, safer and more secure suturing after laparoscopic surgery, resulting in a reduction of the chances of wound herniation.

Withlocals is an online marketplace established in 2013 that specializes in personalized travel experiences. The platform offers over 1,200 customizable and private tours led by approximately 900 verified local hosts across various international cities, primarily in Europe and Asia. Withlocals aims to connect people and cultures through travel, allowing travelers to engage with destinations in an authentic manner, guided by locals who provide insights and experiences off the beaten path. The marketplace facilitates direct connections between hosts and tourists, making personalized travel accessible and affordable for a broad audience. Users can choose activities based on their interests, including food, music, and sports, ensuring a tailored experience that reflects their passions.

GitLab Inc. is a software development company that provides a comprehensive DevSecOps platform designed to enhance the software development lifecycle. Founded in 2011 and headquartered in San Francisco, California, GitLab offers its services through a single application, which includes tools for version control, continuous integration and deployment, code reviews, issue tracking, and collaboration. This unified platform allows organizations to efficiently plan, build, secure, and deploy software while ensuring visibility and control throughout the process. GitLab serves a diverse clientele, ranging from startups to large enterprises, with an estimated 30 million registered users globally. The company operates on an all-remote model, employing over 1,350 team members across more than 65 countries. GitLab is built on open-source principles and benefits from a vibrant community of developers, continuously driving innovations in the DevOps space.

Scenic Biotech, established in 2017 and headquartered in Amsterdam, Netherlands, specializes in developing genomics and immunotherapy technologies to combat cancer and rare genetic diseases. The company's core focus is to identify and harness disease-suppressing genes, which can act as an "off-switch" for genetic disorders, thereby creating novel drug targets and therapies. By leveraging genomics, Scenic Biotech aims to revolutionize the treatment of severe diseases by tackling them at their genetic source.

Blendle is a digital media platform that allows readers to purchase articles from various Dutch and Belgian newspapers and magazines, including prominent publications like the Economist. Users can buy individual articles for prices ranging from €0.10 to €0.30, and they are presented with a selection of recommendations similar to social media feeds. New users are provided with an initial credit of €2.50 to explore the platform. The service includes a brief refund window for article purchases, after which Blendle retains a 30% commission on sales. By offering a pay-per-article model, Blendle aims to enhance access to quality journalism and cater to readers' preferences through personalized recommendations.

Bloomon B.V., founded in 2014 and headquartered in Amsterdam, Netherlands, operates an online retail platform specializing in flower delivery across Europe. The company emphasizes a direct-to-consumer model, sourcing flowers directly from growers to ensure quality. Bloomon offers a subscription service allowing customers to conveniently arrange their orders online, with the flexibility to pause, change, or cancel deliveries without any commitment. This approach enables users to create customized packaging with fresh flowers, enhancing their overall experience. Focused on client satisfaction and product quality, Bloomon prioritizes service over competition in the online flower market.

GitLab Inc. is a software development company that provides a comprehensive DevSecOps platform designed to enhance the software development lifecycle. Founded in 2011 and headquartered in San Francisco, California, GitLab offers its services through a single application, which includes tools for version control, continuous integration and deployment, code reviews, issue tracking, and collaboration. This unified platform allows organizations to efficiently plan, build, secure, and deploy software while ensuring visibility and control throughout the process. GitLab serves a diverse clientele, ranging from startups to large enterprises, with an estimated 30 million registered users globally. The company operates on an all-remote model, employing over 1,350 team members across more than 65 countries. GitLab is built on open-source principles and benefits from a vibrant community of developers, continuously driving innovations in the DevOps space.

NightBalance B.V., established in 2009, is a medical technology company spun out from TU Delft. It specializes in developing innovative solutions to improve patients' sleep, with a focus on treating positional obstructive sleep apnea. The company's flagship product, a Sleep Position Trainer, uses smart technology to monitor and enhance sleep behavior, enabling users to achieve more comfortable and restful nights.

GeoPhy is a developer of an artificial intelligence-driven property analytics platform that leverages both traditional and alternative data sources to deliver instant and accurate valuations for commercial real estate. By utilizing machine learning, GeoPhy helps real estate professionals identify market opportunities and manage risks effectively. The platform provides valuable insights into commercial property values and the factors influencing them, allowing users to assess opportunities based on specific market criteria. Through its innovative approach, GeoPhy aims to enhance transparency and efficiency in the commercial real estate sector.

EclecticIQ is a company specializing in threat intelligence and cybersecurity solutions. It develops advanced technology for threat hunting and response, aimed at enhancing organizations' defenses against cyber adversaries. The company's platform integrates and interprets intelligence data sourced from open sources, commercial suppliers, and industry partnerships. This enables enterprises to bolster their detection, prevention, and response capabilities by embedding actionable intelligence into their cybersecurity infrastructures. Through its offerings, EclecticIQ strives to empower organizations to effectively combat evolving cyber threats.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Crowdynews operates an AI-driven platform that curates social media content for the news media market. The platform automates the integration of real-time, relevant, and safe user-generated content from various social media channels, such as Twitter, Facebook, Instagram, and YouTube, alongside traditional editorial content. By leveraging artificial intelligence and natural language processing, Crowdynews enables media organizations and brands to enhance their storytelling capabilities, incorporating diverse elements like photos, videos, and eyewitness accounts. This approach not only enriches the audience's experience but also aims to drive engagement, improve conversion rates, and increase revenue for its clients.

Wercker is a software company that provides a platform and tools to streamline the development, building, and deployment of containerized applications and microservices in modern cloud environments. Their solution aims to simplify and accelerate the software development lifecycle, enabling businesses and developers to achieve continuous integration and continuous delivery (CI/CD) with ease.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

InteRNA Technologies B.V. is a biotechnology company focused on the development of microRNA (miRNA)-based therapeutics for cancer treatment. The company's innovative approach leverages the unique properties of miRNAs to target previously undruggable pathways involved in cancer initiation, progression, and metastasis. By utilizing advanced techniques such as massively parallel sequencing and proprietary bioinformatics, InteRNA analyzes and validates miRNA sequences to enhance drug efficacy and reduce resistance to existing therapies. Founded in 2006, the company operates from Nijmegen, the Netherlands, and has a dedicated research and development center in Utrecht. Recently, InteRNA has secured additional equity financing to advance its lead program for melanoma treatment, demonstrating its commitment to developing novel solutions in oncology.

Audion Therapeutics BV is a biopharmaceutical company based in Amsterdam, Netherlands, focused on the discovery, development, and commercialization of therapies for ear-related diseases, particularly hearing loss. Founded in 2008, the company is engaged in small molecule drug discovery aimed at regenerating inner hair cells, which are vital for hearing. Audion Therapeutics leverages a unique approach by targeting a protein complex known as gamma-secretase to address sensorineural hearing loss, often associated with aging. The company's intellectual property portfolio comprises new drug molecules, advanced delivery systems, and innovative tools for research in hearing and hearing loss.

Bloomon B.V., founded in 2014 and headquartered in Amsterdam, Netherlands, operates an online retail platform specializing in flower delivery across Europe. The company emphasizes a direct-to-consumer model, sourcing flowers directly from growers to ensure quality. Bloomon offers a subscription service allowing customers to conveniently arrange their orders online, with the flexibility to pause, change, or cancel deliveries without any commitment. This approach enables users to create customized packaging with fresh flowers, enhancing their overall experience. Focused on client satisfaction and product quality, Bloomon prioritizes service over competition in the online flower market.

Shapeways Holdings Inc. is a 3D printing marketplace and community that enables individuals to create, buy, and sell custom products. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company offers a wide range of products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Shapeways operates on a model of on-demand printing, allowing for the customization and personalization of each order. By providing access to advanced 3D printing technology, the platform empowers users to turn their ideas into physical products, fostering creativity and entrepreneurship. Shapeways aims to democratize the manufacturing process by fully digitizing it, making industrial-grade additive manufacturing accessible to a broader audience.

Crowdynews operates an AI-driven platform that curates social media content for the news media market. The platform automates the integration of real-time, relevant, and safe user-generated content from various social media channels, such as Twitter, Facebook, Instagram, and YouTube, alongside traditional editorial content. By leveraging artificial intelligence and natural language processing, Crowdynews enables media organizations and brands to enhance their storytelling capabilities, incorporating diverse elements like photos, videos, and eyewitness accounts. This approach not only enriches the audience's experience but also aims to drive engagement, improve conversion rates, and increase revenue for its clients.

Aito is a technology company specializing in the development and provision of electronic products and solutions that incorporate touch sensations. Their core technology, Piezo Sensing and Haptics, is patented and award-winning, enabling surfaces to respond with tactile feedback. This innovation helps consumer electronics brands differentiate their products in competitive markets by enhancing user experience. Aito's offerings include configurable integrated circuits for real physical user interfaces, such as buttons, touchpads, and touch screens, allowing businesses to improve the touch interfaces of familiar products like smartphones and car infotainment systems.

NPEX operates an online trading platform that connects entrepreneurs with investors, facilitating the trading of securities. The platform is designed to enhance the financing process by offering features such as interest on bonds and access to clear, comprehensive documentation for investors. Additionally, NPEX aids entrepreneurs in increasing brand awareness through media exposure, supporting them in raising funds and issuing stock and bonds. This secure platform provides a streamlined environment for trading, benefiting both companies seeking capital and investors looking for opportunities.

Shapeways Holdings Inc. is a 3D printing marketplace and community that enables individuals to create, buy, and sell custom products. Founded in 2008 and headquartered in New York, with additional offices in Eindhoven and Seattle, the company offers a wide range of products across various categories, including art, fashion, home goods, gadgets, games, jewelry, and miniatures. Shapeways operates on a model of on-demand printing, allowing for the customization and personalization of each order. By providing access to advanced 3D printing technology, the platform empowers users to turn their ideas into physical products, fostering creativity and entrepreneurship. Shapeways aims to democratize the manufacturing process by fully digitizing it, making industrial-grade additive manufacturing accessible to a broader audience.

ViCentra B.V., based in Utrecht, the Netherlands, specializes in the development of medical devices, particularly for diabetes management. The company focuses on creating user-friendly and aesthetically pleasing products that aim to enhance the overall experience for individuals managing their health. ViCentra emphasizes the importance of excellent customer experiences and approaches product design with the belief that simplicity and effectiveness lead to better health outcomes. In addition to its operations in the Netherlands, ViCentra also has a presence in the UK, where it continues to innovate in the field of medical devices through dedicated research and development efforts.

Sapiens Steering Brain Stimulation GmbH is a medical device company focused on advancing deep brain stimulation (DBS) therapy. Founded in 2011 as a spin-out of Royal Philips Electronics, the company aims to enhance patient comfort and therapeutic outcomes with its innovative, high-resolution, and MRI-compatible DBS system. Sapiens specializes in developing a comprehensive DBS solution that includes navigation and steering software, as well as implants specifically designed for patients with Parkinson's disease. With offices in Eindhoven, the Netherlands, and Munich, Germany, Sapiens leverages patented technologies to deliver effective and precise treatment options for individuals suffering from this neurological condition.

Lanthio Pharma B.V. is a biopharmaceutical company based in Groningen, the Netherlands, specializing in the discovery and development of lantipeptide drugs aimed at treating conditions such as fibrosis, stroke, heart failure, and multiple sclerosis. The company employs its proprietary lanthionine-peptide drug discovery technology, LanthioPep™, to create novel peptide therapeutics that exhibit enhanced resistance to peptidase degradation and high receptor specificity. Among its product pipeline are LP2, designed to target fibrosis; PanCyte, intended for ischemic stroke recovery and related conditions; a Lanthi-apelin agonist for various organ systems; and Lanthi-galanin for multiple sclerosis. Founded in 2010, Lanthio Pharma operates as a subsidiary of Morphosys AG, focusing on generating stable, peptidase-resistant peptides that possess high intrinsic activity for several G-protein-coupled receptor targets.

NPEX operates an online trading platform that connects entrepreneurs with investors, facilitating the trading of securities. The platform is designed to enhance the financing process by offering features such as interest on bonds and access to clear, comprehensive documentation for investors. Additionally, NPEX aids entrepreneurs in increasing brand awareness through media exposure, supporting them in raising funds and issuing stock and bonds. This secure platform provides a streamlined environment for trading, benefiting both companies seeking capital and investors looking for opportunities.

Robin Radar Systems B.V., based in The Hague, the Netherlands, specializes in developing radar systems for bird detection and tracking. The company offers several products, including a 2D Mobile system that detects bird presence, number, location, direction, speed, and route over distances of up to 20 kilometers; a 3D Fixed system that provides similar data up to 10 kilometers; and a 3D Flex system that combines horizontal S-band radar with flexible frequency modulated continuous wave radar. Their Military XL system is designed to assist air forces in preventing bird strikes. Robin Radar Systems also offers essential support services such as testing, training, documentation, and maintenance. Established in 2010 as a spin-off from the Dutch Research Institute for Applied Science (TNO), the company has access to advanced radar technology developed for bird tracking since the 1970s. Their innovative solutions aim to enhance safety and sustainability for wind farms, airports, and other operations while minimizing environmental impacts.

ProFibrix B.V. is a biotech company founded in 2004 that specializes in the development and marketing of products for the hemostasis and regenerative medicine markets. The company’s primary product, Fibrocaps, is a dry powder topical hemostat and tissue sealant made from a combination of fibrinogen and thrombin, aimed at stopping acute and severe bleeding during surgical procedures or following traumatic injuries. ProFibrix also provides a sterilized single-use delivery device designed to apply Fibrocaps directly to the target tissue, minimizing disruption to the wound. The company’s products leverage human fibrinogen, a natural blood protein, to enhance hemostasis, blood clotting, and tissue repair.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.